Abstract
In short-term therapy for myasthenia gravis caused by an antibody-mediated attack on the acetylcholine receptor (AChR) in skeletal muscle, a specific system for antibody removal, the use of tryptophan-bound immunoadsorbent and synthetic AChR peptide-bound immunoadsorbent, offers advantages over plasma exchange. These two types of immunoadsorption provided selective or semi-selective removal of pathogenic substances from the circulation without the use of plasma products, and minimized side-effects. A difficulty is that the former removed about 65% of the total IgG, and the latter removed only a fraction of the pathogenic antibodies. In neither case can a radical method of treatment for myasthenia gravis be expected. Hopefully, an adsorbent which has a well-balanced bioimmunological specific binding reaction and physicochemical adsorptive affinity will be developed in the future.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
